265 related articles for article (PubMed ID: 29697418)
21. Oncogene addicted non-small-cell lung cancer: current standard and hot topics.
Vecchiarelli S; Bennati C
Future Oncol; 2018 Jun; 14(13s):3-17. PubMed ID: 29989448
[TBL] [Abstract][Full Text] [Related]
22. Combining inhibitors of ALK and ROS1 with other agents for the treatment of non-small cell lung cancer.
Shaw AT
Clin Adv Hematol Oncol; 2015 May; 13(5):282-4. PubMed ID: 26352769
[No Abstract] [Full Text] [Related]
23. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
Lou NN; Zhang XC; Chen HJ; Zhou Q; Yan LX; Xie Z; Su J; Chen ZH; Tu HY; Yan HH; Wang Z; Xu CR; Jiang BY; Wang BC; Bai XY; Zhong WZ; Wu YL; Yang JJ
Oncotarget; 2016 Oct; 7(40):65185-65195. PubMed ID: 27533086
[TBL] [Abstract][Full Text] [Related]
24. Molecular oncology of lung cancer.
Toyooka S; Mitsudomi T; Soh J; Aokage K; Yamane M; Oto T; Kiura K; Miyoshi S
Gen Thorac Cardiovasc Surg; 2011 Aug; 59(8):527-37. PubMed ID: 21850578
[TBL] [Abstract][Full Text] [Related]
25. Current Approaches in NSCLC Targeting K-RAS and EGFR.
Aran V; Omerovic J
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31739412
[TBL] [Abstract][Full Text] [Related]
26. Precision Management of Advanced Non-Small Cell Lung Cancer.
Yang CY; Yang JC; Yang PC
Annu Rev Med; 2020 Jan; 71():117-136. PubMed ID: 31986082
[TBL] [Abstract][Full Text] [Related]
27. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
[TBL] [Abstract][Full Text] [Related]
28. ALK rearrangements: Biology, detection and opportunities of therapy in non-small cell lung cancer.
Rosas G; Ruiz R; Araujo JM; Pinto JA; Mas L
Crit Rev Oncol Hematol; 2019 Apr; 136():48-55. PubMed ID: 30878128
[TBL] [Abstract][Full Text] [Related]
29. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
[TBL] [Abstract][Full Text] [Related]
30. Predictive markers in lung cancer: a few hints for the practicing pathologist.
Barbareschi M; Barberis M; Buttitta F; Doglioni C; Fiorentino M; Fontanini G; Franco R; Marchetti A; Rossi G; Troncone G
Pathologica; 2018 Mar; 110(1):29-38. PubMed ID: 30259911
[TBL] [Abstract][Full Text] [Related]
31. Resistance to molecularly targeted therapy in non-small-cell lung cancer.
Asao T; Takahashi F; Takahashi K
Respir Investig; 2019 Jan; 57(1):20-26. PubMed ID: 30293943
[TBL] [Abstract][Full Text] [Related]
32. A banner year for immunotherapy and targeted therapy.
Carlisle JW; Ramalingam SS
Nat Rev Clin Oncol; 2019 Feb; 16(2):79-80. PubMed ID: 30538305
[No Abstract] [Full Text] [Related]
33. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
Li W; Zhang Z; Guo L; Qiu T; Ling Y; Cao J; Guo H; Zhao H; Li L; Ying J
Oncotarget; 2016 Feb; 7(7):8332-40. PubMed ID: 26789109
[TBL] [Abstract][Full Text] [Related]
34. Activation of RAS family members confers resistance to ROS1 targeting drugs.
Cargnelutti M; Corso S; Pergolizzi M; Mévellec L; Aisner DL; Dziadziuszko R; Varella-Garcia M; Comoglio PM; Doebele RC; Vialard J; Giordano S
Oncotarget; 2015 Mar; 6(7):5182-94. PubMed ID: 25691052
[TBL] [Abstract][Full Text] [Related]
35. Response to Checkpoint Inhibition in Non-Small Cell Lung Cancer with Molecular Driver Alterations.
Kauffmann-Guerrero D; Tufman A; Kahnert K; Bollmann BA; Reu S; Syunyaeva Z; Schneider C; Manapov F; Huber RM; Golpon H
Oncol Res Treat; 2020; 43(6):289-298. PubMed ID: 32268332
[TBL] [Abstract][Full Text] [Related]
36. Update on systemic therapy of advanced non-small-cell lung cancer.
Cufer T; Knez L
Expert Rev Anticancer Ther; 2014 Oct; 14(10):1189-203. PubMed ID: 25098682
[TBL] [Abstract][Full Text] [Related]
37. New targets and new mechanisms in lung cancer.
Carrizosa DR; Mileham KF; Haggstrom DE
Oncology (Williston Park); 2013 May; 27(5):396-404. PubMed ID: 25184262
[TBL] [Abstract][Full Text] [Related]
38. Novel therapeutic strategies for rare mutations in non-small cell lung cancer.
Gou Q; Gou Q; Gan X; Xie Y
Sci Rep; 2024 May; 14(1):10317. PubMed ID: 38705930
[TBL] [Abstract][Full Text] [Related]
39. ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancer.
Gerber DE; Oxnard GR; Govindan R
Clin Pharmacol Ther; 2015 May; 97(5):447-50. PubMed ID: 25677079
[TBL] [Abstract][Full Text] [Related]
40. Liquid Biopsy and Lung Cancer.
Pisapia P; Malapelle U; Troncone G
Acta Cytol; 2019; 63(6):489-496. PubMed ID: 30566947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]